Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report)’s stock price shot up 3.2% during mid-day trading on Monday . The company traded as high as $6.9150 and last traded at $6.9150. 2,853 shares changed hands during trading, an increase of 0% from the average session volume of 2,848 shares. The stock had previously closed at $6.70.
Clinuvel Pharmaceuticals Trading Up 3.2%
The business has a fifty day moving average of $6.97 and a 200-day moving average of $7.56.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
